<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05065970</url>
  </required_header>
  <id_info>
    <org_study_id>MOR202C206</org_study_id>
    <nct_id>NCT05065970</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy</brief_title>
  <acronym>IGNAZ</acronym>
  <official_title>A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MorphoSys AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MorphoSys AG</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial&#xD;
      and dose evaluation trial of felzartamab in IgAN&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Relative change in Proteinuria value</measure>
    <time_frame>9 months compared to baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: determined by the frequency, incidence and severity of TEAEs</measure>
    <time_frame>Ongoing through study completion, up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Relative change in proteinuria value</measure>
    <time_frame>Ongoing through treatment completion, an average every 3 months per treatment period, up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: complete response in patients with IgAN</measure>
    <time_frame>Ongoing through treatment completion, an average every 3 months per treatment period, up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: serum concentrations of Felzartamab over time</measure>
    <time_frame>Ongoing through treatment completion, up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Immunoglobulin A (IgA) Nephropathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Felzartamab Arm #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Felzartamab Arm #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Felzartamab Arm #3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Felzartamab</intervention_name>
    <description>anti-CD38+ monoclonal antibody</description>
    <arm_group_label>Felzartamab Arm #1</arm_group_label>
    <arm_group_label>Felzartamab Arm #2</arm_group_label>
    <arm_group_label>Felzartamab Arm #3</arm_group_label>
    <other_name>MOR202</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 to ≤ 80 years (at date of signing the informed consent form [ICF]), but&#xD;
             at least of legal age in the given country&#xD;
&#xD;
          -  Biopsy confirmed diagnosis of IgAN within the past 8 years prior to signature of the&#xD;
             ICF&#xD;
&#xD;
          -  Proteinuria at screening visit ≥ 1.0 g/d.&#xD;
&#xD;
          -  Treatment with an angiotensin-converting enzyme inhibitor (ACEi) and/or angiotensin&#xD;
             receptor blocker (ARB) at maximum doses or maximally tolerated doses for ≥ 3 months&#xD;
             prior to date of informed consent and adequate blood pressure (BP) control.&#xD;
&#xD;
          -  A female of childbearing potential (FCBP), is only eligible to participate if she is&#xD;
             not pregnant, not breast feeding, and agrees to follow the contraceptive guidance&#xD;
             during the treatment period and for at least 3 months after the last dose of IMP&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Hemoglobin &lt; 90 g/L&#xD;
&#xD;
          -  Thrombocytopenia: Platelets &lt; 100.0 x 10^9/L.&#xD;
&#xD;
          -  Neutropenia: Neutrophils &lt; 1.5 x 10^9/L.&#xD;
&#xD;
          -  Leukopenia: Leukocytes &lt; 3.0 x 10^9/L&#xD;
&#xD;
          -  Diabetes mellitus type 1&#xD;
&#xD;
          -  Aspartate aminotransferase or alanine aminotransferase &gt;1.5 x ULN, alkaline&#xD;
             phosphatase &gt;3.0 x ULN&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Morphosys Clinical Program Lead</last_name>
    <phone>+498989927</phone>
    <phone_ext>0</phone_ext>
    <email>MOR202C206-CPL@morphosys.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>FOMAT Medical Research - FOMAT - HyperCore - PPDS</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030-5822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Amicis Research Center, Vacaville</name>
      <address>
        <city>Vacaville</city>
        <state>California</state>
        <zip>95687</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedResearch INC</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79935</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunshine Hospital - Australia</name>
      <address>
        <city>Saint Albans</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Imelda VZW</name>
      <address>
        <city>Bonheiden</city>
        <state>Antwerpen</state>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regionaal Ziekenhuis Jan Yperman VZW</name>
      <address>
        <city>Ieper</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Uijeongbu St. Mary's Hospital</name>
      <address>
        <city>Uijeongbu-Si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Lembah Pantai</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centar Zvezdara</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Dr Josep Trueta</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Ruber Juan Bravo (Grupo Quironsalud)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise &quot;Kyiv City Center of Nephrology and Dialysis&quot;</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Institution Institute of Nephrology of NAMS of Ukraine</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Disease</keyword>
  <keyword>Urologic Disease</keyword>
  <keyword>Glomerular Disease</keyword>
  <keyword>Berger Disease</keyword>
  <keyword>Glomerulonephritis, IGA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Felzartamab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

